# ğŸ“… Daily Report - 2025-11-04

> ä»Šæ—¥ç­›é€‰å‡º **42** æ¡å†…å®¹ï¼Œæ¥è‡ª **5** ä¸ªæ¥æº

<div class="powered-by-top">Powered by <a href="https://kyplus.de">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai">Claude</a></div>

---

## ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“

### ğŸ“° å…¬ä¼—å·

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
é¦–æ¬¡æ„å»ºå¥åº·æˆå¹´äººå…ç–«è€åŒ–å…¨æ™¯å›¾ï¼Œç©ºé—´å¤šç»„å­¦æ™ºèƒ½æ•´åˆä¸è°ƒæ§ç½‘ç»œæ¨æ–­ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
- ç»†èƒè¡°è€åœ¨ç–¾ç—…ä¸­çš„ç‰¹å¾ç ”ç©¶ï¼ˆéè‚¿ç˜¤ã€PANoptosisã€CAFç­‰ï¼‰ã€‚
- åŸºäºç»†èƒæ­»äº¡ä¸è¡°è€çš„è‚¿ç˜¤åˆ†å‹åŠæ¨¡å‹æ„å»ºã€‚
- å•ç»†èƒæŠ€æœ¯åœ¨å…ç–«è€åŒ–ã€è‚¿ç˜¤ç ”ç©¶ä¸­çš„åº”ç”¨ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š
- ç©ºé—´å¤šç»„å­¦æ™ºèƒ½æ•´åˆä¸è°ƒæ§ç½‘ç»œæ¨æ–­ã€‚
- å•ç»†èƒæ‰¹æ¬¡æ•´åˆã€å¯å˜å‰ªåˆ‡ã€å‘è‚²æ½œèƒ½é¢„æµ‹ç­‰å·¥å…·ã€‚
- æœºå™¨å­¦ä¹ åœ¨è¡°è€ç›¸å…³ç–¾ç—…ç ”ç©¶ä¸­çš„åº”ç”¨ï¼ˆæ— ç›‘ç£èšç±»ã€åˆ†å‹ç­‰ï¼‰ã€‚
- æ–°å‹è¡°è€åŸºå› é›†é‰´å®šã€‚
- é«˜çº§æ•°æ®å¯è§†åŒ–å·¥å…·ï¼ˆggforceåŒ…ï¼‰ã€‚

### ğŸ§¬ æ•°æ®å‰æ²¿

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
é¦–æ¬¡æ­ç¤ºäº†Aryl Hydrocarbon Receptoræ¿€æ´»é€šè·¯åœ¨æ€¥æ€§å‘¼å¸çª˜è¿«ç»¼åˆå¾ï¼ˆARDSï¼‰ä¸­ï¼Œé€šè¿‡è°ƒæ§è‚ºéƒ¨å…ç–«å’Œä¸Šçš®ç»†èƒå‘æŒ¥çš„ä¿æŠ¤ä½œç”¨ï¼›å¹¶é˜æ˜äº†ORB2 RNAç»“åˆè›‹ç™½é€šè¿‡å…¶Zinc-binding â€˜ZZâ€™ç»“æ„åŸŸåœ¨æœè‡æ—©æœŸå‘è‚²ä¸­é€šè¿‡æŠ‘åˆ¶é¶æ ‡è½¬å½•ç‰©ç¿»è¯‘å‘æŒ¥çš„å…³é”®è°ƒæ§æœºåˆ¶ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
*   **ç‚ç—‡ä¸å…ç–«ç–¾ç—…**ï¼šç ”ç©¶ARDSçš„å…ç–«è°ƒæ§æœºåˆ¶ï¼ŒHIVåˆå¹¶TBæ„ŸæŸ“çš„å®¿ä¸»ååº”ï¼Œä»¥åŠè´¥è¡€ç—‡çš„é¢„åæ ‡å¿—ç‰©ã€‚
*   **ç»†èƒåˆ†åŒ–ä¸å‘è‚²**ï¼šæ¢ç´¢è½¬å½•å› å­è°ƒæ§æ ¸å°ä½“åŠ¨æ€ä¸ç»†èƒåˆ†åŒ–çš„åˆ†å­æœºåˆ¶ï¼Œä»¥åŠRNAç»“åˆè›‹ç™½åœ¨æ—©æœŸå‘è‚²ä¸­çš„ç¿»è¯‘è°ƒæ§ã€‚
*   **ç™Œç—‡è¿›å±•ä¸å¹²é¢„**ï¼šè§£æUGT2B17åœ¨å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè¿›å±•ä¸­çš„éå…¸å‹åŠŸèƒ½ï¼Œä»¥åŠG-quadruplexé¶å‘CRISPR-Cas9çš„è½¬å½•è°ƒæ§æ•ˆåº”ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š
*   **å¤šç»„å­¦æ•´åˆåˆ†æ**ï¼šå¼€å‘äº†ç”Ÿæˆå’Œåˆ†æäººç±»å•æ ¸ç»†èƒæ¥æºå·¨å™¬ç»†èƒçš„å¤šç»„å­¦ï¼ˆåŒ…æ‹¬bulk RNA-Seqï¼‰çš„æ ‡å‡†åŒ–åè®®ã€‚
*   **å•ç»†èƒæŠ€æœ¯åº”ç”¨**ï¼šå¹¿æ³›åº”ç”¨å•ç»†èƒRNAæµ‹åºï¼ˆscRNA-seqï¼‰å’Œå•ç»†èƒATACæµ‹åºï¼ˆscATAC-seqï¼‰æŠ€æœ¯ï¼Œè§£æTregç»†èƒå¯¹IL-2çš„å¼‚è´¨æ€§å“åº”ï¼Œä»¥åŠHIVå¯¹æ½œä¼æ€§TBæ„ŸæŸ“çš„å½±å“ã€‚

### ğŸ”¬ æœŸåˆŠæ–‡ç« 

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
*   æ­ç¤ºéè¥å…»æ€§ç”œå‘³å‰‚é€šè¿‡å½±å“å¾®ç”Ÿç‰©ç¾¤å’Œä»£è°¢ç‰©ï¼ŒæŸå®³æŠ— PD-1 å…ç–«æ²»ç–—çš„ç–—æ•ˆã€‚
*   å‘ç°å‰åˆ—è…ºç™Œä¸­é›„æ¿€ç´ å—ä½“ï¼ˆARï¼‰è›‹ç™½åˆæˆçš„ä»£è°¢è„†å¼±æ€§ï¼Œéš”æ—¥ç¦é£Ÿï¼ˆADFï¼‰å¯æŠ‘åˆ¶ARç¿»è¯‘ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
*   æ¢ç´¢éè¥å…»æ€§ç”œå‘³å‰‚æ‘„å…¥å¯¹ç™Œç—‡å…ç–«æ²»ç–—é•¿æœŸç–—æ•ˆçš„å½±å“ï¼Œå»ºè®®é™åˆ¶å…¶æ‘„å…¥ã€‚
*   åˆ©ç”¨ä»£è°¢è„†å¼±æ€§å¼€å‘æ–°å‹å‰åˆ—è…ºç™Œæ²»ç–—ç­–ç•¥ï¼Œä¾‹å¦‚é€šè¿‡ç¦é£Ÿè¯±å¯¼ARç¿»è¯‘æŠ‘åˆ¶ã€‚
*   è¯„ä¼°GLP-1æ¿€åŠ¨å‰‚åœ¨è‚¥èƒ–æ‚£è€…ç™Œç—‡é£é™©ç®¡ç†ä¸­çš„ä½œç”¨ä¸æœºåˆ¶ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š
*   é€šè¿‡ç ”ç©¶å¾®ç”Ÿç‰©ç¾¤å’Œä»£è°¢ç‰©è°ƒèŠ‚æ¥é˜æ˜éè¥å…»æ€§ç”œå‘³å‰‚å¯¹å…ç–«æ²»ç–—çš„å½±å“ã€‚
*   åˆ©ç”¨éš”æ—¥ç¦é£Ÿï¼ˆADFï¼‰ä½œä¸ºä¸€ç§åº”æ¿€ååº”ï¼Œè¯±å¯¼æ ¸ç³–ä½“ç¢°æ’ä»¥é¶å‘ARç¿»è¯‘ã€‚

### ğŸ“Š å­¦ç‚¹ç”Ÿä¿¡

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
R Shiny BDDæ¡†æ¶å¼•å…¥â€œGivenâ€æ­¥éª¤ï¼Œå®ç°æµ‹è¯•å‰ç½®æ¡ä»¶è®¾ç½®ï¼›maestro 0.7.0å‘å¸ƒï¼Œå®ç°æ¡ä»¶åŒ–æ‰§è¡ŒDAGï¼ˆæœ‰å‘æ— ç¯å›¾ï¼‰ç®¡é“ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
- æå‡R Shinyåº”ç”¨çš„å¯æµ‹è¯•æ€§ä¸å¥å£®æ€§ã€‚
- å¢å¼ºæ•°æ®æµç¨‹ç¼–æ’å·¥å…·çš„çµæ´»æ€§ä¸æ™ºèƒ½åŒ–ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š
- R Shiny BDDä¸­çš„ä¾èµ–æ³¨å…¥ä¸æµ‹è¯•æ›¿èº«æŠ€æœ¯ã€‚
- maestroä¸­åŸºäºæ¡ä»¶åˆ¤æ–­çš„DAGç®¡é“åˆ†æ”¯ä¸æ‰§è¡Œæ§åˆ¶ã€‚

### ğŸ§ª åšå®¢æ›´æ–°

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
å•ç»†èƒRNAæµ‹åºé¦–æ¬¡æ­ç¤ºå·¨å™¬ç»†èƒå¹²æ‰°ç´ ä¿¡å·é€šè·¯ä»‹å¯¼è‚¾ç™Œå…ç–«æ²»ç–—è€è¯æœºåˆ¶ï¼Œä¸ºç”Ÿç‰©æ ‡å¿—ç‰©å‘ç°å’Œæ²»ç–—ç­–ç•¥ä¼˜åŒ–æä¾›æ–°æ€è·¯ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
- æ¢ç´¢å¹²æ‰°ç´ ä¿¡å·åœ¨è‚¾ç™Œå…ç–«æ²»ç–—è€è¯ä¸­çš„ä½œç”¨
- è§£æé•¿è¯»é•¿RNAæµ‹åºåœ¨åŒºåˆ†é¡ºå¼å’Œåå¼å‰ªæ¥è°ƒæ§ä¸­çš„åº”ç”¨
- åˆ©ç”¨äºŒä»£åŸºå› æµ‹åºæŠ€æœ¯æå‡å…½åŒ»è¯Šæ–­èƒ½åŠ›å’ŒåŠ¨ç‰©å¥åº·ç›‘æµ‹æ°´å¹³

**æŠ€æœ¯äº®ç‚¹**ï¼š
- é•¿è¯»é•¿RNAæµ‹åºï¼ˆlong-read RNA-seqï¼‰æŠ€æœ¯
- å•ç»†èƒRNAæµ‹åºï¼ˆsingle-cell RNA sequencingï¼‰æŠ€æœ¯

---

## ğŸ“š åˆ†ç±»æµè§ˆ

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ“° å…¬ä¼—å· (13æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨13æ¡ï¼‰

**1.** â­ **å¥åº·æˆå¹´äººå…ç–«è€åŒ–å…¨æ™¯å›¾ï¼›ç©ºé—´å¤šç»„å­¦æ™ºèƒ½æ•´åˆä¸è°ƒæ§ç½‘ç»œæ¨æ–­ã€å•ç»†èƒæ‰¹æ¬¡æ•´åˆã€å•ç»†èƒå¯å˜å‰ªåˆ‡ã€å‘è‚²æ½œèƒ½é¢„æµ‹ç­‰å·¥å…·ä¸Šæ–° |å•ç»†èƒè§†è§’**
- âœï¸ **ä½œè€…**ï¼šå•ç»†èƒå¤©åœ°
- ğŸ·ï¸ **å…³é”®è¯**ï¼šå…ç–«ã€å•ç»†èƒã€ç©ºé—´ç»„å­¦
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzI1Njk4ODE0MQ==&mid=2247533477&idx=1&sn=daf8c8ee0fd42dcd889437aac72a9a76)

**2.** â­ **9.4åˆ†éè‚¿ç˜¤ç”Ÿä¿¡ï¼Œè¡°è€+æœºå™¨å­¦ä¹ +åˆ†å‹+å…ç–«æµ¸æ¶¦+è¡¨è¾¾éªŒè¯ã€‚è¿™æˆ‘ä¹Ÿèƒ½åšå‘€ï¼**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡å°è¯¾å ‚
- ğŸ·ï¸ **å…³é”®è¯**ï¼šè‚¿ç˜¤ã€å…ç–«ã€ç”Ÿä¿¡
- ğŸ“ **æè¿°**ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&mid=2247503824&idx=4&sn=8f76b0533d1a608e8bb2ea6c4d894ade)

**3.** â­ **éè‚¿ç˜¤çº¯ç”Ÿä¿¡ï¼ŒåŸºäºæœºå™¨å­¦ä¹ ï¼Œæ— ç›‘ç£èšç±»ç­‰ç ”ç©¶ç»†èƒè¡°è€åœ¨ç–¾ç—…ä¸­çš„ç‰¹å¾ã€‚è¡°è€çƒ­ç‚¹ç»ä¹…ä¸è¡°ï¼**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡å°è¯¾å ‚
- ğŸ·ï¸ **å…³é”®è¯**ï¼šè‚¿ç˜¤ã€ç”Ÿä¿¡ã€èšç±»
- ğŸ“ **æè¿°**ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&mid=2247503824&idx=2&sn=c47f1a491567d4f934a11206dce7e27a)

**4.** â­ **æœ€æ–°8.1åˆ†éè‚¿ç˜¤ç”Ÿä¿¡ï¼Œé’ˆå¯¹PANoptosisçƒ­ç‚¹è¿›è¡Œæœºå™¨å­¦ä¹ +å•ç»†èƒç­›é€‰+ç®€å•éªŒè¯ï¼Œå…¨æ–‡åªæœ‰4ä¸ªFigureï¼**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡å°è¯¾å ‚
- ğŸ·ï¸ **å…³é”®è¯**ï¼šè‚¿ç˜¤ã€å•ç»†èƒã€ç”Ÿä¿¡
- ğŸ“ **æè¿°**ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&mid=2247503824&idx=1&sn=57ca959a005a04d9cd4410f16d895348)

**5.** â­ **å¤æ—¦å¤§å­¦å‘ Nat Cancer |ä¸´åºŠè¯•éªŒ+å•ç»†èƒæµ‹åºï¼Œçœ‹çœ‹ä»–ä»¬æ˜¯æ€ä¹ˆåšçš„**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡é’±åŒå­¦
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€æµ‹åºã€å•ç»†èƒ
- ğŸ“ **æè¿°**ï¼šä¸´åºŠå®éªŒé…åˆå•ç»†èƒæµ‹åº
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzkwMzY2NjkwNg==&mid=2247495403&idx=1&sn=464b38cbd7349648d4d8113aec4d6f0c)

**6.** **æœ€æ–°5.7åˆ†ç”Ÿä¿¡ï¼Œå•ç»†èƒæ³›ç™Œ+ç©ºè½¬æ³›ç™Œ+ç™¾ç§æœºå™¨å­¦ä¹ ç ”ç©¶CAFçš„è¡°è€è¡¨å‹ï¼ŒæŠ•ç¨¿åˆ°æ¥æ”¶ä»…48å¤©ï¼Œå¯è°“æ˜¯æ°´åˆŠä¸­çš„å¤©èŠ±æ¿ï¼**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡å°è¯¾å ‚
- ğŸ·ï¸ **å…³é”®è¯**ï¼šå•ç»†èƒã€ç”Ÿä¿¡
- ğŸ“ **æè¿°**ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&mid=2247503824&idx=7&sn=a41c1eee969ebc64c35bd1079c262907)

**7.** **5æœˆæœ€æ–°10+ç”Ÿä¿¡ï¼ŒåŸºäºç»†èƒæ­»äº¡å’Œè¡°è€çš„è‚¿ç˜¤åˆ†å‹åŠæ¨¡å‹æ„å»ºï¼Œåˆ†æä¸éš¾ï¼Œå®éªŒåªæœ‰åŠä¸ªfigureï¼Œå€¼å¾—å­¦ä¹ ï¼**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡å°è¯¾å ‚
- ğŸ·ï¸ **å…³é”®è¯**ï¼šè‚¿ç˜¤ã€ç”Ÿä¿¡
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&mid=2247503824&idx=6&sn=34a846bbfdc98165c172a8b3b8d8f4ef)

**8.** **15.7åˆ†çº¯ç”Ÿä¿¡ï¼ŒåŸºäºå•ç»†èƒæ„å»ºç»†èƒè¡°è€çš„ç»†èƒç±»å‹ç‰¹å¼‚æ€§å›¾è°±ã€‚è‡ªå®šä¹‰ç®—æ³•é‰´å®šå‡ºæ–°çš„è¡°è€åŸºå› é›†ï¼**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡å°è¯¾å ‚
- ğŸ·ï¸ **å…³é”®è¯**ï¼šå•ç»†èƒã€ç”Ÿä¿¡
- ğŸ“ **æè¿°**ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&mid=2247503824&idx=3&sn=1eacdde390df0a070b63975b9c529cbe)

**9.** **è›‹ç™½è´¨ç»„è½¬å½•ç»„åˆ†æä¸¤ä¸‰äº‹ï¼šKEGGå·²ç»ä¸æ˜¯ä»¥å‰çš„KEGGäº†**
- âœï¸ **ä½œè€…**ï¼šDr.Xçš„åŸºå› ç©ºé—´
- ğŸ·ï¸ **å…³é”®è¯**ï¼šè½¬å½•ç»„ã€è›‹ç™½è´¨ç»„
- ğŸ“ **æè¿°**ï¼šæ—§ä»£ç éœ€è¦å®šæœŸæ£€æŸ¥è¿è¡Œç¨³å®šæ€§ï¼Œç‰¹åˆ«æ˜¯ä»£ç ä¸­ä¾èµ–åˆ°ç¬¬ä¸‰æ–¹æ•°æ®åº“å’Œç½‘ç«™æ—¶ï¼Œéœ€è¦è­¦æƒ•å¤–éƒ¨å˜åŒ–ä¸ºå†…éƒ¨åˆ†æå¸¦æ¥ä¸å¯å¿½è§†çš„å½±å“
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzU3MTc2NDI4Mw==&mid=2247486659&idx=1&sn=b3d0fd6f227a91f5306e359763dbb5ed)

**10.** **metaforåŒ…:é€‰æ‹©æ¨¡å‹ï¼ˆSelection Modelsï¼‰**
- âœï¸ **ä½œè€…**ï¼šR å­¦ä¹ è·µè¡Œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šTMEã€RåŒ…
- ğŸ“ **æè¿°**ï¼šé€‰æ‹©æ¨¡å‹ç”¨äºæ¨¡æ‹Ÿåœ¨ Meta åˆ†æä¸­è¢«çº³å…¥ç ”ç©¶çš„è¿‡ç¨‹å¯èƒ½å—åˆ°å‘è¡¨åå€šå½±å“çš„æœºåˆ¶ã€‚å¦‚æœæŸä¸ªç‰¹å®šçš„é€‰æ‹©æ¨¡å‹èƒ½å¤Ÿè¾ƒå¥½åœ°è¿‘ä¼¼æ½œåœ¨çš„é€‰æ‹©è¿‡ç¨‹ï¼Œé‚£ä¹ˆè¯¥æ¨¡å‹å°±èƒ½ç»™å‡ºé’ˆå¯¹æ„Ÿå…´è¶£å‚æ•°çš„â€œæ ¡æ­£åâ€ä¼°è®¡å€¼ï¼Œå³è¿™äº›å‚æ•°åœ¨é€‰æ‹©å‘ç”Ÿä¹‹å‰çš„ç ”ç©¶æ€»ä½“ä¸­çš„ä¼°è®¡ã€‚
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzkzNzY2NDgyOQ==&mid=2247493101&idx=1&sn=ceef86351c934a18781ac3fdc7ac937d)

**11.** **Nature Geneticsæ‚å¿—ç‰¹åˆ«ç‰ˆå•ç»†èƒmarkeråŸºå› æ°”æ³¡å›¾**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡æŠ€èƒ½æ ‘
- ğŸ·ï¸ **å…³é”®è¯**ï¼šTMEã€å•ç»†èƒ
- ğŸ“ **æè¿°**ï¼šå›æ—‹é•–æ¥äº†ï¼
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzAxMDkxODM1Ng==&mid=2247546635&idx=1&sn=8a9fbdb461f7c704e07e61f054b3e200)

**12.** **åˆ°ç°åœ¨è¿˜ä¸ä¼šç”¨ggforceåŒ…ï¼Ÿä¸‰åˆ†é’Ÿå¸¦ä½ ç©è½¬é«˜çº§æ•°æ®å¯è§†åŒ–ï¼Œè®©ä½ çš„å›¾è¡¨ç¬é—´é«˜å¤§ä¸Šï¼**
- âœï¸ **ä½œè€…**ï¼šäº‘ç”Ÿä¿¡
- ğŸ·ï¸ **å…³é”®è¯**ï¼šRåŒ…
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=Mzg5MDk3Mzg4OA==&mid=2247498404&idx=1&sn=d6615b113ae6d19bc0137f3cbfe0ed10)

**13.** **å†¬å¤©åˆ°äº†ï¼Œç©ºè°ƒç”µè´¹çœäº†ï¼Œç»™å¤§å®¶åšç‚¹æœåŠ¡å™¨åŒ 11 æ´»åŠ¨ï¼Œä¾¿æ·å¼ç”Ÿä¿¡äº‘æœåŠ¡å™¨**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡é’±åŒå­¦
- ğŸ·ï¸ **å…³é”®è¯**ï¼šç”Ÿä¿¡
- ğŸ“ **æè¿°**ï¼šç”Ÿä¿¡äº‘æœåŠ¡å™¨é™æ—¶ 8 æŠ˜ï¼Œå¦å¤–é…ç½®ä¹Ÿå‡çº§äº†
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzkwMzY2NjkwNg==&mid=2247495414&idx=1&sn=80a30c4ee87a6a6bb2bf379eafbb6847)


</div>

</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (20æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨20æ¡ï¼‰

**1.** â­ **GSE309106 å•ç»†èƒ RNA æµ‹åºæ­ç¤ºäº†èŠ³çƒƒå—ä½“æ¿€æ´»é€šè¿‡æ¶‰åŠè‚ºéƒ¨å…ç–«ç»†èƒå’Œä¸Šçš®ç»†èƒçš„å¤šæ¡é€šè·¯å‡è½»æ€¥æ€§å‘¼å¸çª˜è¿«ç»¼åˆå¾**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€cancerã€immuneã€immunityã€TMEã€cardiacã€gliomaã€resistanceã€TCGAã€sequencingã€RNAseqã€single.cellã€single-cellã€scRNAã€scDNAã€scATACã€spatialã€spatiallyã€Visiumã€genomeã€genomicsã€transcriptomeã€proteomeã€Seuratã€Scanpyã€epigeneticã€epigenomeã€methylationã€histoneã€pathwayã€clustering
- ğŸ“ **æè¿°**ï¼šContributor : Mitzi NagarkattiSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusAcute Respiratory Distress Syndrome (ARDS) is a severe inflammatory lung disorder triggered by pneumonia, sepsis, trauma, and COVID-19, leading to high mortality. In this study, we investigated the effect of Aryl Hydrocarbon Receptor (AhR) activation by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a potent ligand, on LPS-induced ARDS in mice using single-cell RNA sequencing (scRNA-seq). scRNA-seq revealed sixteen transcriptionally distinct cell clusters in the lungs. AhR activation reversed the decreased pulmonary functions caused by LPS, and significantly reduced pulmonary infiltration of monocytes, neutrophils, and macrophages. Interestingly, AhR activation during ARDS led to increased proportions of alveolar macrophages, and angiogenic and quiescent endothelial cells (AECs and QECs, respectively). Among the downregulated pathways, prostaglandin signaling was the most broadly suppressed across many cell types in the LPS+TCDD group. AhR activation suppressed the neutrophil chemotaxis pathway involving Cxcl2, Cxcl3, and Cxcl10. The damage to endothelial and epithelial cells induced during ARDS was also blocked by AhR activation. This was associated with decreased expression of S100a8 and S100a9. Notably, multiple pathways related to cellular junction organization were enriched following AhR activation. Additionally, Scgb1a1, also called Club cell protein 16 (CC16), primarily secreted by Club cells in the respiratory epithelium, was highly upregulated following AhR activation accounting for lung homeostasis. Together, these findings demonstrate that AhR activation mitigates key inflammatory and barrier-disruptive processes involving multiple cell types in LPS-induced ARDS. These data identify AhR as a central regulator of pulmonary inflammation and epithelialâ€“endothelial integrity and support the future evaluation of AhR-targeted therapeutics as potential treatment for ARDS.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309106)

**2.** â­ **GSE300680 äººç±»å•æ ¸ç»†èƒè¡ç”Ÿå·¨å™¬ç»†èƒçš„ç”Ÿæˆå’Œå¤šç»„å­¦åˆ†æçš„ç®€åŒ–å’Œç»¼åˆæ–¹æ¡ˆ [bulk RNA-Seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€cancerã€oncologyã€immuneã€TMEã€gliomaã€TCGAã€DepMapã€depmapã€RNA-seqã€RNAseqã€DNA-seqã€ChIP-seqã€ATAC-seqã€Hi-Cã€scRNAã€scDNAã€scATACã€spatialã€spatiallyã€Visiumã€genomeã€genomicsã€proteomeã€proteomicsã€epigeneticã€epigenomeã€histone
- ğŸ“ **æè¿°**ï¼šContributors : Olivia G Palmer ; Laurent Perreard ; Fred W Kolling IV ; Patricia A Pioli ; Brittany A GoodsSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensMacrophages are versatile immune cells with phenotypes ranging from inflammatory (M1-like) to anti-inflammatory (M2-like), shaped by diverse differentiation and polarization conditions. We present a standardized protocol to generate and characterize human macrophages from frozen PBMC-derived monocytes using cytokine profiling, transcriptomics, and snRNA-seq, including depolarization studies. This streamlined approach facilitates reproducible macrophage studies from biobanked samples, advancing both research and therapeutic applications.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300680)

**3.** â­ **GSE299661 ORB2 RNAç»“åˆè›‹ç™½é€šè¿‡å…¶åŠŸèƒ½ä¿å®ˆçš„é”Œç»“åˆâ€œZZâ€ç»“æ„åŸŸï¼Œåœ¨æœè‡æ¯ä½“å‘åˆå­è½¬å˜è¿‡ç¨‹ä¸­æŠ‘åˆ¶å…¶é¶è½¬å½•æœ¬çš„ç¿»è¯‘ã€‚**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€cancerã€oncologyã€carcinomaã€TMEã€gliomaã€resistanceã€TCGAã€Hi-Cã€single.cellã€scRNAã€scDNAã€scATACã€spatialã€spatiallyã€genomeã€genomicsã€transcriptomeã€transcriptomicsã€proteomeã€proteomicsã€Seuratã€epigeneticã€epigenomeã€histoneã€enrichment
- ğŸ“ **æè¿°**ï¼šContributors : Timothy C Low ; Hua Luo ; Chalini Weerasooriya ; Sichun Lin ; Stephane Angers ; Craig A Smibert ; Howard D LipshitzSeries Type : Expression profiling by high throughput sequencingOrganism : Drosophila melanogasterRNA-binding proteins (RBPs) are key components of the post-transcriptional regulatory machinery. We show that the ORB2 RBP, the Drosophila ortholog of vertebrate Cytoplasmic Polyadenylation Element Binding Protein 2 (CPEB2), binds to hundreds of maternally provided mRNAs in early embryos, identify a U-rich motif enriched in ORB2â€™s targets, and show that this motif confers ORB2 binding and repression to a luciferase reporter mRNA in S2 tissue culture cells. ORB2â€™s target transcripts are translationally repressed and unstable during the maternal-to-zygotic transition (MZT), a developmental phase during which a large proportion of maternally provided mRNAs are repressed and cleared. We show that, when tethered to a luciferase reporter, ORB2 and its human homolog CPEB2 (but not ORB and CPEB1) repress translation and that the C-terminal Zinc-binding (â€˜ZZâ€™) domain of ORB2 is sufficient for repression. ORB2 interacts with a suite of post-transcriptional regulators in early embryos; a subset of these interactions is lost upon deletion of the ZZ domain, notably with the Cup repressive complex. Analysis of the early embryoâ€™s translatome in the presence or absence of the endogenous ZZ domain, shows that ORB2â€™s targets move onto polysomes upon ZZ domain deletion, indicating that this domain mediates translational repression of ORB2â€™s targets during the MZT. Together, our results assign a function to the ZZ domain and support a significant role for ORB2 in post-transcriptional regulation of maternal mRNAs during the Drosophila MZT.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299661)

**4.** â­ **GSE299140 æœè‡æ¯æºå‘åˆå­è½¬å˜è¿‡ç¨‹ä¸­ï¼ŒORB2 RNAç»“åˆè›‹ç™½é€šè¿‡å…¶åŠŸèƒ½ä¿å®ˆçš„é”Œç»“åˆâ€œZZâ€ç»“æ„åŸŸæŠ‘åˆ¶é¶è½¬å½•æœ¬çš„ç¿»è¯‘ã€‚**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€cancerã€oncologyã€carcinomaã€TMEã€gliomaã€resistanceã€TCGAã€Hi-Cã€single.cellã€scRNAã€scDNAã€scATACã€spatialã€spatiallyã€genomeã€genomicsã€transcriptomeã€transcriptomicsã€proteomeã€proteomicsã€Seuratã€epigeneticã€epigenomeã€histoneã€enrichment
- ğŸ“ **æè¿°**ï¼šContributors : Timothy CH Low ; Hua Luo ; Chalini Weerasooriya ; Sichun Lin ; Stephane Angers ; Craig A Smibert ; Howard D LipshitzSeries Type : Expression profiling by high throughput sequencingOrganism : Drosophila melanogasterRNA-binding proteins (RBPs) are key components of the post-transcriptional regulatory machinery. We show that the ORB2 RBP, the Drosophila ortholog of vertebrate Cytoplasmic Polyadenylation Element Binding Protein 2 (CPEB2), binds to hundreds of maternally provided mRNAs in early embryos, identify a U-rich motif enriched in ORB2â€™s targets, and show that this motif confers ORB2 binding and repression to a luciferase reporter mRNA in S2 tissue culture cells. ORB2â€™s target transcripts are translationally repressed and unstable during the maternal-to-zygotic transition (MZT), a developmental phase during which a large proportion of maternally provided mRNAs are repressed and cleared. We show that, when tethered to a luciferase reporter, ORB2 and its human homolog CPEB2 (but not ORB and CPEB1) repress translation and that the C-terminal Zinc-binding (â€˜ZZâ€™) domain of ORB2 is sufficient for repression. ORB2 interacts with a suite of post-transcriptional regulators in early embryos; a subset of these interactions is lost upon deletion of the ZZ domain, notably with the Cup repressive complex. Analysis of the early embryoâ€™s translatome in the presence or absence of the endogenous ZZ domain, shows that ORB2â€™s targets move onto polysomes upon ZZ domain deletion, indicating that this domain mediates translational repression of ORB2â€™s targets during the MZT. Together, our results assign a function to the ZZ domain and support a significant role for ORB2 in post-transcriptional regulation of maternal mRNAs during the Drosophila MZT.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299140)

**5.** â­ **GSE299109 æœè‡æ¯æºå‘åˆå­è½¬å˜è¿‡ç¨‹ä¸­ï¼ŒORB2 RNAç»“åˆè›‹ç™½é€šè¿‡å…¶åŠŸèƒ½ä¿å®ˆçš„é”Œç»“åˆâ€œZZâ€ç»“æ„åŸŸæŠ‘åˆ¶é¶è½¬å½•æœ¬çš„ç¿»è¯‘ã€‚**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€cancerã€oncologyã€carcinomaã€TMEã€gliomaã€resistanceã€TCGAã€Hi-Cã€single.cellã€scRNAã€scDNAã€scATACã€spatialã€spatiallyã€genomeã€genomicsã€transcriptomeã€transcriptomicsã€proteomeã€proteomicsã€Seuratã€epigeneticã€epigenomeã€histoneã€enrichment
- ğŸ“ **æè¿°**ï¼šContributors : Timothy C Low ; Hua Luo ; Chalini Weerasooriya ; Sichun Lin ; Stephane Angers ; Craig A Smibert ; Howard D LipshitzSeries Type : Expression profiling by high throughput sequencingOrganism : Drosophila melanogasterRNA-binding proteins (RBPs) are key components of the post-transcriptional regulatory machinery. We show that the ORB2 RBP, the Drosophila ortholog of vertebrate Cytoplasmic Polyadenylation Element Binding Protein 2 (CPEB2), binds to hundreds of maternally provided mRNAs in early embryos, identify a U-rich motif enriched in ORB2â€™s targets, and show that this motif confers ORB2 binding and repression to a luciferase reporter mRNA in S2 tissue culture cells. ORB2â€™s target transcripts are translationally repressed and unstable during the maternal-to-zygotic transition (MZT), a developmental phase during which a large proportion of maternally provided mRNAs are repressed and cleared. We show that, when tethered to a luciferase reporter, ORB2 and its human homolog CPEB2 (but not ORB and CPEB1) repress translation and that the C-terminal Zinc-binding (â€˜ZZâ€™) domain of ORB2 is sufficient for repression. ORB2 interacts with a suite of post-transcriptional regulators in early embryos; a subset of these interactions is lost upon deletion of the ZZ domain, notably with the Cup repressive complex. Analysis of the early embryoâ€™s translatome in the presence or absence of the endogenous ZZ domain, shows that ORB2â€™s targets move onto polysomes upon ZZ domain deletion, indicating that this domain mediates translational repression of ORB2â€™s targets during the MZT. Together, our results assign a function to the ZZ domain and support a significant role for ORB2 in post-transcriptional regulation of maternal mRNAs during the Drosophila MZT.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299109)

**6.** â­ **GSE293173 HIV å¯¹ Mtb/SIV å…±æ„ŸæŸ“æ’æ²³çŒ´æ¨¡å‹ä¸­æ½œä¼æ€§ç»“æ ¸æ„ŸæŸ“å½±å“çš„å•ç»†èƒè½¬å½•ç»„å­¦ç ”ç©¶ [scRNA-seq cART+3HP]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€cancerã€carcinomaã€immuneã€TMEã€cardiacã€gliomaã€RNA-seqã€RNAseqã€DNA-seqã€ATAC-seqã€Hi-Cã€single.cellã€scRNAã€scDNAã€scATACã€spatialã€genomeã€genomicsã€transcriptomeã€transcriptomicsã€Seuratã€histoneã€enrichment
- ğŸ“ **æè¿°**ï¼šContributors : Riti Sharan ; Yi Zou ; Korri Weldon ; Zhao Lai ; Deepak KaushalSeries Type : Expression profiling by high throughput sequencingOrganism : Macaca mulattaWe studied components of TB immunity that remain impaired after cART in the lung compartment, versus those that are restored by concurrent 3 months of once weekly isoniazid and rifapentine (3HP) and cART in the rhesus macaque (RM) model of LTBI and Simian Immunodeficiency Virus (SIV) co-infection. Concurrent administration of cART+3HP did improve clinical and microbiological attributes of Mtb/SIV co-infection compared to cART-naÃ¯ve or -untreated RMs. While RMs in the cART+3HP group exhibited significantly lower granuloma volumes after treatment, they, however, continued to harbor caseous granulomas with increased FDG uptake. cART only partially restores the constitution of CD4+ T cells to the lung compartment in co-infected macaques. Concurrent therapy did not further enhance the frequency of reconstituted CD4+ T cells in BAL and lung of Mtb/SIV co-infected RMs compared to cART, and treated animals continued to display incomplete reconstitution to the lung. Furthermore, the reconstituted CD4+ T cells in BAL and lung of cART+3HP treated RMs exhibited an increased frequencies of activated, exhausted and inflamed phenotype compared to LTBI RMs. cART+3HP failed to restore the effector memory CD4+ T cell population that was significantly reduced in pulmonary compartment post SIV co-infection. Concurrent therapy was associated with the induction of Type I IFN transcriptional signatures and led to increased Mtb-specific TH1/TH17 responses correlated with protection, but decreased Mtb-specific TNFï¡ responses, which could have a detrimental impact on long term protection.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293173)

**7.** â­ **GSE268719 å…ˆé”‹è½¬å½•å› å­ä¹‹é—´çš„åˆ†å­å’Œä¸Šä½æ€§ç›¸äº’ä½œç”¨å¡‘é€ æ ¸å°ä½“åŠ¨åŠ›å­¦å’Œç»†èƒåˆ†åŒ–**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€carcinomaã€TMEã€metabolicã€metabolomeã€metabolomicsã€cardiacã€gliomaã€resistanceã€scRNAã€scDNAã€scATACã€spatialã€genomeã€genomicsã€transcriptomeã€transcriptomicsã€proteomeã€proteomicsã€Seuratã€Scanpyã€methylationã€enrichment
- ğŸ“ **æè¿°**ï¼šContributors : RÃ©mi-Xavier Coux ; Pablo NavarroSeries Type : Expression profiling by high throughput sequencing ; Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusThis SuperSeries is composed of the SubSeries listed below.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE268719)

**8.** â­ **GSE300681 äººç±»å•æ ¸ç»†èƒè¡ç”Ÿå·¨å™¬ç»†èƒçš„ç”Ÿæˆå’Œå¤šç»„å­¦åˆ†æçš„ç®€åŒ–å’Œç»¼åˆæ–¹æ¡ˆ**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€cancerã€oncologyã€immuneã€TMEã€gliomaã€TCGAã€DepMapã€depmapã€Hi-Cã€scRNAã€scDNAã€scATACã€spatialã€spatiallyã€Visiumã€genomeã€genomicsã€proteomeã€proteomicsã€epigeneticã€epigenome
- ğŸ“ **æè¿°**ï¼šContributors : Olivia G Palmer ; Laurent Perreard ; Fred W Kolling IV ; Patricia A Pioli ; Brittany A GoodsSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensMacrophages are versatile immune cells with phenotypes ranging from inflammatory (M1-like) to anti-inflammatory (M2-like), shaped by diverse differentiation and polarization conditions. We present a standardized protocol to generate and characterize human macrophages from frozen PBMC-derived monocytes using cytokine profiling, transcriptomics, and snRNA-seq, including depolarization studies. This streamlined approach facilitates reproducible macrophage studies from biobanked samples, advancing both research and therapeutic applications.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300681)

**9.** â­ **GSE302849 å‰ç²’è›‹ç™½é€šè¿‡ä½œç”¨äºæ˜Ÿå½¢èƒ¶è´¨ç»†èƒä¿ƒè¿›æµ·é©¬ç¥ç»å…ƒçš„æ ‘çªç”Ÿé•¿**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šoncologyã€immuneã€immunityã€TMEã€gliomaã€TCGAã€scRNAã€scATACã€spatialã€genomeã€genomicsã€proteomeã€proteomicsã€Seuratã€histoneã€enrichment
- ğŸ“ **æè¿°**ï¼šContributors : Azariah K Kaplelach ; Justin A Hall ; Wren O Nader ; Amelia G Davidson ; Margaret D Ireland ; Lara Ianov ; Andrew E ArrantSeries Type : Expression profiling by high throughput sequencingOrganism : Rattus norvegicusProgranulin is a secreted pro-protein that is trafficked to lysosomes and exerts protective effects in the brain. Progranulin (GRN) mutations, most of which cause progranulin haploinsufficiency, are a major genetic cause of frontotemporal dementia (FTD). Restoring progranulin to people with GRN mutations is a promising treatment strategy, but understanding progranulinâ€™s mechanism of action may enable design of optimal progranulin-based therapies. Progranulin restrains inflammation and promotes neuronal growth and survival, but the mechanisms underlying these effects are unclear. Progranulin is constitutively secreted and interacts with various signaling receptors, but is also taken up and trafficked to lysosomes, where it is necessary for maintaining normal lysosomal function. In previous work, we showed that progranulin acts in lysosomes to promote neuronal survival, but it is not clear if progranulin enhances neuronal growth by acting in lysosomes or through extracellular signaling. To address this question, we employed lentiviral vectors expressing either progranulin (PGRN) or a non-secreted, lysosome-targeted progranulin (L-PGRN). Using lentiviral vectors driven by non-selective (PGK), neuron-selective (hSyn), or astrocyte-selective (GFAP) promoters, we found that delivering L-PGRN to astrocytes, but not neurons, promoted dendritic outgrowth in primary hippocampal cultures. Using transwell co-cultures of astrocytes and neurons, we found that neurons cultured with L-PGRNâ€“transduced astrocytes had greater dendritic outgrowth than those cultured with GFP-transduced astrocytes. Bulk RNA sequencing of primary astrocytes indicated that L-PGRN reduced transcriptomic pathways associated with inflammation and cellular reactivity. Consistent with this result, we found that reducing the number of astrocytes in hippocampal cultures increased dendritic outgrowth and occluded the pro-growth effects of L-PGRN. These data show that under these culture conditions, progranulin secretion is not required to promote dendritic outgrowth. Instead, progranulin may act via a non-cellâ€“autonomous mechanism to suppress secretion of factors from astrocytes that restrain neuronal growth. These data add to a growing body of evidence that progranulin can act ...
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302849)

**10.** â­ **GSE302070 Treg å¯¹ç™½ç»†èƒä»‹ç´ -2 ååº”çš„å¼‚è´¨æ€§å’ŒåŒè´¨æ€§ [RNAseq2ï¼šIL2 å…ç–«ç»†èƒå› å­å¯¹å…ç–«ç»†èƒç±»å‹çš„å·®å¼‚æ€§æ¿€æ´»]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šimmuneã€TMEã€kinaseã€resistanceã€RNA-seqã€RNAseqã€Hi-Cã€single.cellã€single-cellã€spatialã€spatiallyã€genomeã€genomicsã€Seuratã€Scanpyã€histone
- ğŸ“ **æè¿°**ï¼šContributors : Kumba Seddu ; Kaitavjeet Chowdhary ; Odhran Casey ; Molly Henderson ; Yi Cao ; Jakub Tomala ; Liang Yang ; Jamie Spangler ; Diane Mathis ; Christophe BenoistSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusIL2 is an immune-regulatory cytokine that activates both effector and T regulatory cellsâ€”a dual function leveraged in immunotherapy. However, pure IL2 induces both activation and suppression, and requires toxic doses due to its short half-life. To address this, the Spangler Lab at Johns Hopkins developed IL2 immunocytokines (IL2-ICs)â€”antibody-conjugated IL2 fusion proteins targeting IL2Ra (Tregs) or IL2Rb (effector cells), with extended serum half-life. We tested IL2-ICs in Foxp3IRES-GFP mice, harvesting cells at 4, 24, and 64 hours post-injection for bulk RNA-seq. Transcriptomic analysis showed IL2-ICs induced sustained IL2 responses with partial cell-type bias.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302070)

**11.** â­ **GSE277340è½¬å½•ç»„åˆ†ææ­ç¤ºäº†Hedgehogä¿¡å·é€šè·¯ä½œä¸ºç”Ÿç‰©æ ‡å¿—ç‰©åœ¨æ¢…å†…ç‰¹é‡Œå°”ç—…å‘ç—…æœºåˆ¶ä¸­çš„ä½œç”¨**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šTMEã€gliomaã€kinaseã€TCGAã€scRNAã€scDNAã€spatialã€genomeã€genomicsã€transcriptomeã€transcriptomicsã€proteomeã€epigenomeã€histoneã€enrichment
- ğŸ“ **æè¿°**ï¼šContributors : Miyoung Shin ; Tryston T Gabriel ; Fred Kwame Ofosu ; Jiali Zhang ; Tricia T Wang ; Matthew E Bechard ; Robert J Coffey ; Won Jae HuhSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensBoth MÃ©nÃ©trierâ€™s disease (MD) and juvenile polyposis syndrome (JPS) are rare premalignant conditions that can lead to gastric cancer. MD is an acquired disease without known causative mutations that is characterized by increased expression of an EGF receptor (EGFR) ligand, transforming growth factor-alpha (TGFÎ±), in the stomach. JPS is inherited in an autosomal dominant pattern and is caused by BMPR1A or SMAD4 mutations. Although there are distinct clinico-pathological features that differ between the two diseases, they also share similar features that often lead to misdiagnosis. To identify diagnostic markers for MD and to better understand the pathogenesis of the disease, we performed transcriptomic profiling of stomach tissues from normal (NL), MD, and JPS patients. Comparative analysis between MD and JPS revealed both common and differential gene signatures. Common gene signatures included estrogen receptor signaling, integrin signaling, mTOR signaling, and others, which may be responsible for histopathological similarities. Among differential gene signatures, we found that Hedgehog (Hh) signaling is upregulated in MD and confirmed that protein expression of Hh signaling downstream targets, GLI1 (glioma-associated oncogene homolog 1) and HHIP (Hedgehog-interacting protein), is higher in MD than in JPS, particularly in foveolar cells by immunohistochemistry. We also showed that treatment with an Hh pathway inhibitor partially rescued the histopathological phenotypes in an MD mouse model. This study provides valuable insights into the potential mechanisms underlying the similar clinico-pathological features observed in MD and JPS. We also identified GLI1 and HHIP as diagnostic markers that can help to distinguish MD from JPS. Furthermore, Hh signaling was shown to play an important role in the pathogenesis of MD and can function as a potential therapeutic target.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE277340)

**12.** â­ **GSE299316 Treg å¯¹ç™½ç»†èƒä»‹ç´ -2 ååº”çš„å¼‚è´¨æ€§å’ŒåŒè´¨æ€§ [scATAC-seq1: IL2 2h å’Œ PBS Ctl]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šTMEã€kinaseã€RNA-seqã€RNAseqã€DNA-seqã€ATAC-seqã€Hi-Cã€single.cellã€single-cellã€scATACã€spatialã€genomeã€genomicsã€histone
- ğŸ“ **æè¿°**ï¼šContributors : Kaitavjeet Chowdhary ; Kumba Seddu ; Christophe BenoistSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusWe investigated early effects of IL2 treatment on mouse Treg chromatin accessibility by performing scATAC-seq on splenic Tregs isolated from mice 2h after treatment with recombinant IL2 or PBS vehicle control.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299316)

**13.** â­ **GSE272769 å…¨è¡€è½¬å½•ç»„åˆ†æé‰´å®šå‡ºè„“æ¯’ç—‡æ­»äº¡ç‡çš„è¡¨è¾¾ç‰¹å¾**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€oncologyã€TMEã€gliomaã€TCGAã€scRNAã€scDNAã€spatialã€genomeã€genomicsã€transcriptomeã€transcriptomicsã€Seurat
- ğŸ“ **æè¿°**ï¼šContributors : Blanca E Himes ; Nuala J Meyer ; Mengyuan KanSeries Type : Expression profiling by arrayOrganism : Homo sapiensSepsis is the leading cause of death in U.S. hospitals and affects nearly 50 million people globally per year. Sepsis is defined as the â€˜dysregulated host response to infectionâ€™, however, identifying specific and targetable immune abnormalities for therapeutic intervention has been challenging. An effective immune response clears pathogen but also protects host tissues from collateral damage. In sepsis, however, broad immune dysregulation causes organ failure and increased risk of mortality. Therapeutic trials targeting known inflammatory markers in sepsis have failed to improve outcomes. Efforts to identify sepsis therapies may have been thwarted by a focus on the wrong targets, undetected or unaccounted-for heterogeneity among study participants, or issues of timing in a highly dynamic immune response and clinical syndrome.Analysis of the leukocyte transcriptome can reveal elements of the dysregulated host response to infection that characterizes sepsis. We hypothesized that sepsis nonsurvivors have a distinct transcriptional signature, and we thus sought to identify, validate, and contextualize the whole blood transcriptomic changes associated with sepsis mortality in patients with and without septic shock.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE272769)

**14.** â­ **GSE301342 Treg å¯¹ç™½ç»†èƒä»‹ç´ -2 ååº”çš„å¼‚è´¨æ€§å’ŒåŒè´¨æ€§ [scRNA-seq: IL2/JES6-1 æ—¶é—´åºåˆ—]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€TMEã€kinaseã€RNA-seqã€RNAseqã€DNA-seqã€Hi-Cã€scRNAã€genomeã€genomicsã€Seuratã€histone
- ğŸ“ **æè¿°**ï¼šContributors : Kumba Seddu ; Kaitavjeet Chowdhary ; Molly Henderson ; Jakub Tomala ; Odhran Casey ; Yi Cao ; Diane Mathis ; Jamie Spangler ; Christophe BenoistSeries Type : Expression profiling by high throughput sequencing ; OtherOrganism : Mus musculusInterleukin-2 (IL2) is the key trophic factor for T Regulatory (Treg) cells, regulating both their differentiation and homeostasis. To understand how temporally regulated responses to IL2 unfold in Tregs, we performed fine time-course analyses at single-cell level induced by IL2 in Tregs in vivo. The data revealed responses that were largely uniform in resting Treg, but diverse among activated or effector Tregs, matching different STAT5 signal transduction efficiency. Individual Tregs displayed divergences in the preponderance of changes downstream of STAT1 or STAT5.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301342)

**15.** â­ **GSE299361 Treg å¯¹ç™½ç»†èƒä»‹ç´ -2 ååº”çš„å¼‚è´¨æ€§å’ŒåŒè´¨æ€§ [scATAC-seq2: IL2/JES6-1 æ—¶é—´è¿›ç¨‹]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€TMEã€kinaseã€RNA-seqã€RNAseqã€DNA-seqã€ATAC-seqã€Hi-Cã€scATACã€genomeã€genomicsã€histone
- ğŸ“ **æè¿°**ï¼šContributors : Kaitavjeet Chowdhary ; Kumba Seddu ; Christophe BenoistSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusWe investigated the dynamic effects of IL2 exposure on Treg chromatin accessibility over time by performing scATAC-seq on splenic Tregs isolated from mice at mulitple timepoints (1,2,4,8,16,32,64,128hours) after treatment with IL2/JES6-1 complexes or PBS vehicle control.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299361)

**16.** â­ **GSE279769 åˆ©ç”¨é…ä½“åŠŸèƒ½åŒ–çš„ CRISPR-Cas9 å¯¹å•ä¸ª G-å››é“¾ä½“è¿›è¡Œé¶å‘ï¼Œæ­ç¤ºäº†è½¬å½•ä¾èµ–æ€§åŠŸèƒ½ååº”ã€‚**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€Hi-Cã€single.cellã€single-cellã€scRNAã€scDNAã€scATACã€spatialã€Seuratã€epigeneticã€histone
- ğŸ“ **æè¿°**ï¼šContributors : Sabrina Pia Nuccio ; Enrico Cadoni ; Roxani Nikoloudaki ; Silvia Galli ; An-Jie Ler ; Thomas E Maher ; Ella Fan ; Ling Sum Liu ; Christopher R Fullenkamp ; John S Schneekloth Jr ; Marco Di AntonioSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe development of selective ligands to target DNA G-quadruplexes (G4s) has been pivotal in revealing their role in transcriptional regulation. However, most of the ligands described to date lack intra-G4 selectivity, severely limiting their potential for uncovering the biological function of individual G4s across the genome. To overcome these limitations, we developed ATENA (Approach to Target Exact Nucleic Acid alternative structures). ATENA relies on the chemical modification of established G4-ligands to enable their conjugation onto a catalytically inactive Cas9 protein (dCas9) using HaloTag, allowing for the targeting of individual G4s in living cells. We have systematically screened the length of the PEG-linkers connecting the G4-ligands to the HaloTag and sgRNA sequences to attain optimal G4 engagement both in vitro and in cells. Using optimized conditions, we leveraged ATENA to demonstrate how the selective targeting of the well-studied G4 in the promoter of the oncogene c-MYC suppresses its transcription exclusively from the P1 promoter. We also show that positioning ligands in the proximity of regulatory elements suppresses c-MYC transcription in a G4-independent manner, highlighting the importance of appropriate design to measure genuine G4-mediated transcriptional changes. We also demonstrate that selective targeting of a G4 in the PVT1 promoter can either stimulate or repress its transcription depending on the type of G4-ligand used, indicating that functional responses associated with G4-stabilization can highly depend on the type of ligand used. We further harnessed ATENA to study transcriptional perturbation associated with cell-specific G4s, revealing that the functional responses associated with these structures are tightly linked with the expression levels of the targeted gene. Our study provides critical insights into G4-based therapeutic design, offering an innovative platform to investigate G4 biology with high precision.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE279769)

**17.** â­ **GSE292707 UGT2B17çš„éç»å…¸åŠŸèƒ½ä¿ƒè¿›å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œçš„è¿›å±•**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€cancerã€TMEã€gliomaã€resistanceã€scRNAã€scATACã€genomeã€genomicsã€Seuratã€clustering
- ğŸ“ **æè¿°**ï¼šContributors : Xuesen Dong ; Nathan Lack ; Tunc MorovaSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensWhen prostate cancer (PCa) overcomes the androgen receptor (AR) target therapy and progresses to the castrate-resistant prostate cancer (CRPC) stage, it becomes curable. UDP glucuronosyltransferase 2B17 (UGT2B17) is the key enzyme determining androgen bioavailability to AR inside PCa cells. However, whether UGT2B17 promotes CRPC progression remains poorly understood. Here, we report that anti-AR therapy increases UGT2B17 protein stability. UGT2B17 is localized in both the cytoplasm and nucleus to exert multiple non-enzymatic functions. In the cytoplasm, UGT2B17 activates unfolded protein response (UPR) to counteract endoplasmic reticulum (ER) stress for cell survival. UGT2B17 can exert its nuclear functions by stimulating c-Src kinase to activate AR in the absence of androgens. The UGT2B17-Src axis confers PCa cells resistant to DNA damage and promotes cell cycling by passing the G2 checkpoints through de-activating ATM and ATR kinases. We conclude that these non-enzymatic functions of UGT2B17 activate multiple survival pathways to allow CRPC progression.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292707)

**18.** â­ **GSE296893 ç ”ç©¶å‘ç°ï¼Œæ¥å—æŠ—é€†è½¬å½•ç—…æ¯’æ²»ç–—çš„ HIV æ„ŸæŸ“è€…ä¸­ï¼ŒæŒç»­å­˜åœ¨çš„è‚ºç‚çƒèŒå®šæ¤ä¸é¼»è…”ç‚ç—‡ç›¸å…³ã€‚**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€carcinomaã€TMEã€cardiacã€gliomaã€scRNAã€scDNAã€scATACã€spatialã€Seurat
- ğŸ“ **æè¿°**ï¼šContributors : Joseph Aston Phiri ; Kondwani Charles JamboSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensWe have employed a single cell RNA sequencing approach to study the nasal immune and epithelial cells landscape in People Living with HIV (PLHIV) and during the course of anti-retroviral uptake. The landscape ansal immunity is crucial for early control of respiratory pathogens including bacterian and viruses.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296893)

**19.** â­ **GSE296240 Treg å¯¹ç™½ç»†èƒä»‹ç´ -2 ååº”çš„å¼‚è´¨æ€§å’ŒåŒè´¨æ€§ [RNAseq1: IL2/JES6-1 æ—¶é—´åºåˆ—]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€TMEã€kinaseã€RNA-seqã€RNAseqã€Hi-Cã€genomeã€genomicsã€Seuratã€histone
- ğŸ“ **æè¿°**ï¼šContributors : Kumba Seddu ; Kaitavjeet Chowdhary ; Odhran Casey ; Molly Henderson ; Yi Cao ; Jakub Tomala ; Liang Yang ; Jamie Spangler ; Diane Mathis ; Christophe BenoistSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusIL2 is an immune-regulatory cytokine that is crucial for the development and maintenance of Tregs. Here we investigate how temporal IL2 stimulation affects Treg gene expression and chromatin landscape via RNASeq and ATACSeq
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296240)

**20.** â­ **GSE297025 Tregç»†èƒå¯¹ç™½ç»†èƒä»‹ç´ -2ååº”çš„å¼‚è´¨æ€§å’ŒåŒè´¨æ€§**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šTMEã€genomeã€histone
- ğŸ“ **æè¿°**ï¼šSeries Type : Genome binding/occupancy profiling by high throughput sequencing ; Expression profiling by high throughput sequencing ; OtherOrganism : Mus musculusThis SuperSeries is composed of the SubSeries listed below.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297025)


</div>

</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ”¬ æœŸåˆŠæ–‡ç«  (4æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨4æ¡ï¼‰

**1.** **äººé€ ç”œå‘³å‰‚åœ¨ç™Œç—‡å…ç–«æ²»ç–—ä¸­çš„è‹¦æ¶©å›å‘³**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šç™Œç—‡ã€å…ç–«
- ğŸ“ **æè¿°**ï¼šSecret hovertext: æ‘˜è¦ï¼šMorderã€Nguyenã€Wilfahrt åŠå…¶åŒäº‹æŠ¥å‘Šè¯´ï¼Œéè¥å…»æ€§ç”œå‘³å‰‚é€šè¿‡æ¶‰åŠå¾®ç”Ÿç‰©ç¾¤å’Œä»£è°¢ç‰©è°ƒèŠ‚çš„æœºåˆ¶æŸå®³æŠ— PD-1 æ²»ç–—çš„ç–—æ•ˆã€‚ä»–ä»¬çš„ç ”ç©¶ç»“æœå¼ºè°ƒäº†å¤šç§ç™Œç—‡ç±»å‹é•¿æœŸç”Ÿæ´»æ–¹å¼å¹²é¢„çš„ä¸´åºŠç›¸å…³æ€§ï¼Œä¾‹å¦‚é™åˆ¶éè¥å…»æ€§ç”œå‘³å‰‚çš„æ¯æ—¥æ‘„å…¥é‡ã€‚å‚è§ Morder ç­‰äººçš„ç›¸å…³æ–‡ç« ï¼Œç¬¬ 2278 é¡µ
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://m.x-mol.com/paper/1985400838140108800/t)

**2.** **åˆ©ç”¨å‰åˆ—è…ºç™Œä¸­çš„ AR ååŒä»£è°¢è„†å¼±æ€§**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šä»£è°¢
- ğŸ“ **æè¿°**ï¼šSecret hovertext: å¯¹é›„æ¿€ç´ å‰¥å¤ºç–—æ³•çš„è€è¯æ€§ä»ç„¶æ˜¯å‰åˆ—è…ºç™Œçš„ä¸»è¦ä¸´åºŠæŒ‘æˆ˜ï¼Œéœ€è¦æ›¿ä»£æ²»ç–—ç­–ç•¥ã€‚é›„æ¿€ç´ å—ä½“ ï¼ˆARï¼‰ é€šè¿‡å¢å¼º AR ä¿¡å·ä¼ å¯¼ã€DNA ä¿®å¤å’Œè‡ªå™¬ç­‰æœºåˆ¶åœ¨é©±åŠ¨è€è¯æ€§æ–¹é¢å‘æŒ¥æ ¸å¿ƒä½œç”¨ã€‚åœ¨æœ¬æœŸã€Šç™Œç—‡ç ”ç©¶ã€‹ä¸­ï¼ŒCordova åŠå…¶åŒäº‹å‘ç°äº† AR è›‹ç™½åˆæˆä¸­çš„ä»£è°¢è„†å¼±æ€§ï¼Œè¡¨æ˜éš”æ—¥ç¦é£Ÿ ï¼ˆADFï¼‰ é€šè¿‡è¯±å¯¼ AR mRNA ä¸Šçš„æ ¸ç³–ä½“ç¢°æ’æ¥æŸå®³ AR ç¿»è¯‘ã€‚è¿™ç§åº”æ¿€ååº”æ¿€æ´»æ¿€é…¶ï¼Œä¾‹å¦‚ p38 MAPKï¼Œå¹¶é€‰æ‹©æ€§åœ°é™ä½ AR è›‹ç™½æ°´å¹³ï¼Œä¸è½¬å½•æˆ–è›‹ç™½è´¨ç¨³å®šæ€§æ— å…³ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼ŒADF å¢å¼ºäº†æ©æ‚é²èƒºåœ¨å¤šç§å‰åˆ—è…ºç™Œæ¨¡å‹ä¸­çš„ç–—æ•ˆã€‚ä¸ä¼ ç»Ÿçš„ AR é¶å‘æ–¹æ³•ä¸åŒï¼ŒADF æ­ç¤ºäº†è¥å…»èƒè¿«ä¸‹ AR è¡¨è¾¾çš„è½¬å½•åä¾èµ–æ€§ï¼ŒåŒæ—¶ä¿ç•™äº†å¤§å¤šæ•°å…¶ä»–è›‹ç™½è´¨ã€‚è¿™äº›å‘ç°å‡¸æ˜¾äº†å‰åˆ—è…ºç™Œä¸­ä¸€ç§æ–°çš„è½¬åŒ–è„†å¼±æ€§ï¼Œå¹¶æ”¯æŒå°†é¥®é£Ÿå¹²é¢„ä¸ AR é¶å‘ç–—æ³•ç›¸ç»“åˆï¼Œä»¥å…‹æœè€è¯æ€§å¹¶æ”¹å–„æ‚£è€…çš„é¢„åã€‚å‚è§ Cordova ç­‰äººçš„ç›¸å…³æ–‡ç« ï¼Œç¬¬ 4182 é¡µ
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://m.x-mol.com/paper/1985400849754136576/t)

**3.** **GLP-1 æ¿€åŠ¨å‰‚ä¼šå‰Šå¼±è‚¥èƒ–ä¸ç™Œç—‡ä¹‹é—´çš„è”ç³»å—ï¼Ÿ**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šç™Œç—‡
- ğŸ“ **æè¿°**ï¼šSecret hovertext: æ‘˜è¦ï¼šèƒ°é«˜è¡€ç³–ç´ æ ·è‚½1å—ä½“æ¿€åŠ¨å‰‚åœ¨é€†è½¬è‚¥èƒ–ç—‡æ‚£è€…çš„ä¸€äº›ç™Œç—‡é£é™©æ–¹é¢æœ‰å¾ˆå¤§çš„å¸Œæœ›ï¼Œåˆ°ç›®å‰ä¸ºæ­¢ï¼Œæ–°å…´çš„ä¸´åºŠè¯•éªŒæ”¯æŒè¿™ä¸€ç‚¹ã€‚ç„¶è€Œï¼Œä¸€äº›ä¸´åºŠå‰å·¥ä½œå’Œäººä½“ç ”ç©¶çš„è­¦å‘Šå¼ºè°ƒï¼Œéœ€è¦æ›´å¤šçš„å·¥ä½œæ¥äº†è§£æŠ—è‚¥èƒ–è¯ç‰©åœ¨ç™Œç—‡ä¸­çš„æœºåˆ¶å’Œå…¨éƒ¨æ½œåŠ›ã€‚
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://m.x-mol.com/paper/1985400844523839488/t)

**4.** **ä»åˆ›æ–°åˆ°å½±å“åŠ›ï¼šå…±åŒæ¨è¿›ç™Œç—‡ç ”ç©¶**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šç™Œç—‡
- ğŸ“ **æè¿°**ï¼šSecret hovertext: æ‘˜è¦ï¼šç™Œç—‡ç ”ç©¶å·²è¿›å…¥ä¸€ä¸ªå˜é©æ—¶ä»£ï¼Œå…¶ç‰¹ç‚¹æ˜¯å…ç–«ç–—æ³•ã€æ—©æœŸæ£€æµ‹ã€ç²¾å‡†è‚¿ç˜¤å­¦å’Œäººå·¥æ™ºèƒ½çš„å¿«é€Ÿè¿›æ­¥æ­£åœ¨é‡å¡‘é¢„é˜²ã€æ²»ç–—å’Œç”Ÿå­˜ç‡ã€‚ä¸ºäº†ä¿æŒåŠ¿å¤´ï¼Œå…¨çƒç™Œç—‡ç•Œå¿…é¡»å›´ç»•æŠ•èµ„ã€åˆä½œå’Œå…¬å¹³å›¢ç»“èµ·æ¥ï¼Œä»¥ç¡®ä¿æ¯ä½æ‚£è€…éƒ½èƒ½ä»è¿™äº›çªç ´ä¸­å—ç›Šã€‚
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://m.x-mol.com/paper/1985400861754040320/t)


</div>

</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ“Š å­¦ç‚¹ç”Ÿä¿¡ (2æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨2æ¡ï¼‰

**1.** **R Shiny ä¸­çš„è¡Œä¸ºé©±åŠ¨å¼€å‘ï¼šä½¿ç”¨ç»™å®šæ­¥éª¤è®¾ç½®æµ‹è¯•å‰ææ¡ä»¶**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šHi-Cã€histone
- ğŸ“ **æè¿°**ï¼šLearn how to set up test preconditions in Shiny BDD using Given steps. Master dependency injection, test doubles, and composable setup patterns for reliable R testing. Continue reading: Behavior-Driven Development in R Shiny: Setting Up Test Preconditions with Given Steps
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.r-bloggers.com/2025/11/behavior-driven-development-in-r-shiny-setting-up-test-preconditions-with-given-steps/)

**2.** **Maestro 0.7.0 å¼•å…¥äº†æ¡ä»¶ç®¡é“**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šscDNA
- ğŸ“ **æè¿°**ï¼šThe 0.7.0 release of maestro is out, and with it is the ability to conditionally run pipelines. In a nutshell, this is especially useful when you have DAG pipelines and you want to branch or only execute parts of a DAG when the output meets a pa... Continue reading: maestro 0.7.0 introduces conditional pipelines
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.r-bloggers.com/2025/11/maestro-0-7-0-introduces-conditional-pipelines/)


</div>

</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (3æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨3æ¡ï¼‰

**1.** â­ **åˆ©ç”¨å•ç»†èƒRNAæµ‹åºè§£ç è‚¾ç™Œä¸­çš„å¹²æ‰°ç´ ä¿¡å·é€šè·¯**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€kinaseã€TCGAã€sequencingã€RNA-seqã€RNAseqã€DNA-seqã€Hi-Cã€single.cellã€single-cellã€scRNAã€scATAC
- ğŸ“ **æè¿°**ï¼šSingle-cell RNA sequencing reveals how interferon signaling in macrophages drives resistance to immunotherapy in renal cell carcinoma, offering new insights for biomarker discovery and treatment strategies...
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.rna-seqblog.com/decoding-interferon-signaling-in-kidney-cancer-with-single-cell-rna-sequencing/)

**2.** â­ **isoLASERé•¿è¯»é•¿RNAæµ‹åºå¯åŒºåˆ†é¡ºå¼å’Œåå¼å®šå‘çš„RNAé€‰æ‹©æ€§å‰ªæ¥**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€cardiacã€resistanceã€RNA-seqã€RNAseqã€DNA-seqã€scRNAã€scDNAã€scATAC
- ğŸ“ **æè¿°**ï¼šRNA sequencing using long-read technology reveals how cis- and trans-acting elements control splicing in disease-related genes including MAPT and BIN1...
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.rna-seqblog.com/isolaser-long-read-rna-seq-demarcates-cis-and-trans-directed-alternative-rna-splicing/)

**3.** â­ **ä»å®éªŒå®¤åˆ°ç”Ÿç‰©ä¿¡æ¯å­¦ï¼šæ„å»ºä¸‹ä¸€ä»£åŸºå› æµ‹åºç½‘ç»œ**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šTMEã€kinaseã€TCGAã€sequencingã€RNAseqã€bioinformaticsã€histone
- ğŸ“ **æè¿°**ï¼šRNA sequencing advances are empowering veterinary diagnosticians to detect emerging pathogens faster and improve animal health surveillance through hands-on training in next-generation sequencing and bioinformatics...
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.rna-seqblog.com/from-bench-to-bioinformatics-networking-the-next-generation-in-genetic-sequencing/)


</div>

</details>

## ğŸ“Š å…³é”®è¯ç»Ÿè®¡

| å…³é”®è¯ | å‡ºç°æ¬¡æ•° |
|--------|----------|
| TME | 22 |
| genome | 18 |
| scRNA | 17 |
| histone | 17 |
| genomics | 17 |
| scATAC | 16 |
| spatial | 15 |
| Hi-C | 14 |
| scDNA | 14 |
| Seurat | 14 |
| cancer | 13 |
| glioma | 13 |
| tumor | 13 |
| TCGA | 11 |
| RNAseq | 11 |
| RNA-seq | 9 |
| single.cell | 9 |
| proteome | 9 |
| kinase | 8 |
| resistance | 8 |

---

*ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-11-04 00:32*  
*ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ*